HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $1.2

Benzinga Newsdesk www.benzinga.com Neutral 69.5%

Neg 0% Neu 69.5% Pos 0%

HC Wainwright & Co. analyst Douglas Tsao maintains AEON Biopharma (AMEX:AEON) with a Buy and lowers the price target from $5 to $1.2.